Your browser doesn't support javascript.
loading
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Bruyer, Angelique; Maes, Ken; Herviou, Laurie; Kassambara, Alboukadel; Seckinger, Anja; Cartron, Guillaume; Rème, Thierry; Robert, Nicolas; Requirand, Guilhem; Boireau, Stéphanie; Müller-Tidow, Carsten; Veyrune, Jean-Luc; Vincent, Laure; Bouhya, Salahedine; Goldschmidt, Hartmut; Vanderkerken, Karin; Hose, Dirk; Klein, Bernard; De Bruyne, Elke; Moreaux, Jerome.
Afiliação
  • Bruyer A; IGH, CNRS, Univ Montpellier, Montpellier, France.
  • Maes K; Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
  • Herviou L; IGH, CNRS, Univ Montpellier, Montpellier, France.
  • Kassambara A; IGH, CNRS, Univ Montpellier, Montpellier, France.
  • Seckinger A; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Cartron G; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Rème T; UFR de Médecine, Univ Montpellier, Montpellier, France.
  • Robert N; Department of Clinical Hematology, CHU Montpellier, Montpellier, France.
  • Requirand G; Univ Montpellier, UMR CNRS 5235, Montpellier, France.
  • Boireau S; IGH, CNRS, Univ Montpellier, Montpellier, France.
  • Müller-Tidow C; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Veyrune JL; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Vincent L; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Bouhya S; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Goldschmidt H; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Vanderkerken K; IGH, CNRS, Univ Montpellier, Montpellier, France.
  • Hose D; Department of Biological Haematology, CHU Montpellier, Montpellier, France.
  • Klein B; Department of Clinical Hematology, CHU Montpellier, Montpellier, France.
  • De Bruyne E; Department of Clinical Hematology, CHU Montpellier, Montpellier, France.
  • Moreaux J; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Br J Cancer ; 118(8): 1062-1073, 2018 04.
Article em En | MEDLINE | ID: mdl-29500406
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmócitos / Protocolos de Quimioterapia Combinada Antineoplásica / Epigênese Genética / Reprogramação Celular / Inibidores de Histona Desacetilases / Mieloma Múltiplo Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmócitos / Protocolos de Quimioterapia Combinada Antineoplásica / Epigênese Genética / Reprogramação Celular / Inibidores de Histona Desacetilases / Mieloma Múltiplo Idioma: En Ano de publicação: 2018 Tipo de documento: Article